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ABSTRACT
Objective To evaluate whether systemic corticosteroids
improve symptoms of sore throat in adults and children.
Design Systematic review and meta-analysis.
Data sources Cochrane Central, Medline, Embase,
Database of Reviews of Effectiveness (DARE), NHS Health
Economics Database, and bibliographies.
Outcomemeasures Percentageof patients withcomplete
resolutionat24and48hours,meantimetoonsetofpain
relief, mean time to complete resolution of symptoms,
daysmissedfromworkorschool,recurrence,andadverse
events.
ResultsWeincludedeighttrials,consistingof743patients
in total (369 children, 374 adults). 348 (47%) had
exudative sore throat, and 330 (44%) were positive for
group A β-haemolytic streptococcus. In addition to
antibiotics and analgesia, corticosteroids significantly
increased the likelihood of complete resolution of pain at
24hours(fourtrials)bymorethanthreetimes(relativerisk
3.2, 95% confidence interval 2.0 to 5.1), and at 48 hours
(three trials) to a lesser extent (1.7, 1.3 to 2.1).
Corticosteroids (six trials) reduced mean time to onset of
pain relief by more than 6 hours (95% confidence interval
3.4 to 9.3, P<0.001), although significant heterogeneity
was present. The mean time to complete resolution was
inconsistent across trials and a pooled analysis was not
undertaken. Reporting of other outcomes was limited.
Conclusions Corticosteroids provide symptomatic relief
of pain in sore throat, in addition to antibiotic therapy,
mainly in participants with severe or exudative sore
throat.
INTRODUCTION
Sore throat is a common reason for people to seek
medical care, accounting for about one in 50 of all
ambulatory care visits and resulting in considerable
costs.
1-4 Most sore throats are self limiting
5 and are
caused by rhinovirus, coronavirus, or adenovirus.
Group A β-haemolytic streptococcus is responsible
for about 10% of sore throats in adults and 15–30% of
those in children.
16
Treatment of sore throat with antibiotics provides
only modest beneficial effect in reducing symptoms
and fever.
78 However, prescribing rates remain
disproportionately high.
6 High rates of antibiotic pre-
scriptions contribute to antibiotic resistance
9 and also
lead to the “medicalising” of sore throat, which can
result in increased rates of patient (re)attendance.
1011
In developed countries, prescribing is no longer justi-
fied to prevent complications from group A β-haemo-
lytic streptococcus infection. Peritonsillar abscess
occurs in fewer than two in 10000 patients presenting
with acute respiratory tract infections,
12 whereas non-
suppurative complications (such as rheumatic fever
and glomerulonephritis) are extremely rare.
81314
The pressure for clinicians to reduce antibiotic pre-
scriptions for sore throat leaves a therapeutic vacuum.
Corticosteroids inhibit transcription of proinflamma-
tory mediators in human airway endothelial cells
which cause pharyngeal inflammation and ultimately
symptoms of pain.
15 Corticosteroids are beneficial in
other upper respiratory tract infections such as acute
sinusitis, croup, and infectious mononucleosis.
16-18
We therefore hypothesised that corticosteroids would
offer similar symptomatic relief from sore throat
because of their anti-inflammatory effects, and under-
took a systematic review to examine the effect of sys-
temic corticosteroids on adults and children with sore
throat.
METHODS
Search strategy and selection
We included only randomised controlled trials com-
paring systemic corticosteroids with placebo, in chil-
dren or adults, in outpatient (ambulatory) settings.
We also included studies of patients with clinical
signs of acute tonsillitis or pharyngitis (inflammation
of the tonsils or oropharynx) and patients with a clin-
ical syndrome of “sore throat” (painful throat, odyno-
phagia). We excluded studies of infectious
mononucleosis, sore throat following tonsillectomy
or intubation, or peritonsillar abscess.
WesearchedMedline(1966to2008),Embase(1983
to 2008), the Cochrane Library including the
Cochrane Central register of Controlled Trials (CEN-
TRAL), the Database of reviews of effectiveness
(DARE), and the NHS Health Economics Database
from the beginning of each database until August
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19 Terms
used included “upper respiratory tract infection”,
“pharyngitis”,“tonsillitis”,“sorethroat”,and“corticos-
teroids” (including “dexamethasone”, “betametha-
sone”, “prednisone”, and all variations of these terms)
and viral and bacterial upper respiratory pathogens
(full search strategy available from authors). Two
authors independently reviewed the title and abstracts
of electronic searches, obtaining the full articles to
assess for relevance where necessary. Disagreements
were resolved by discussion with a third author. We
did citation searches of all full-text papers retrieved.
Data extraction and quality assessment
Twoauthorsindependentlyassessedstudyqualityand
extracted data using an extraction template. Disagree-
ments were documented and resolved by discussion
with a third author. We assessed methodological
quality ofstudiesby allocationconcealment,randomi-
sation, comparability of groups on baseline character-
istics, blinding, treatment adherence, and percentage
participation.
Primary outcomes included the proportion of parti-
cipants with improvement or complete resolution of
symptoms,meantimestoonsetofpainrelief,andcom-
pleteresolutionofpain.Secondaryoutcomesincluded
the reduction in pain measured by visual analogue
scale, adverse events necessitating discontinuation of
treatment, relapse rates, and days missed from school
or work. Where necessary, data were extracted from
graphs with the Grab It XP Microsoft Excel program
(www.datatrendsoftware.com)
We did sensitivity analyses, excluding each study in
turn, to determine the stability of the effect. A priori
subgroup analyses included age, route of corticoster-
oid,presenceofpositivebacterialcultureordirectanti-
gen test, and severity of sore throat including presence
of exudate. Meta-regression in STATA tested
subgroup interaction on the outcomes. We selected
the data closest to a single-dose regimen from those
studies that used different dosing regimens in a single
trialasourconservativestrategy.Similarly,ifbothoral
and intramuscular data were available, we used oral
data for our overall analysis and intramuscular data
for appropriate subgroup analysis.
Data synthesis and analysis
We expressed dichotomous outcomes as relative risks
and 95% confidence intervals and expressed continu-
ous variables as weighted mean difference and 95%
confidenceintervals.Ifdataweresufficientforprimary
outcomes, we calculated the number needed to treat
using the relative risk and the pooled event rates, in
additiontotheriskdifferenceascalculatedinRevMan
4.2. We used the I
2 statistic to measure the proportion
of statistical heterogeneity for each outcome.
20 Where
no heterogeneity was present, we undertook a fixed
effect meta-analysis. If substantial heterogeneity (I
2
above 50%) was detected, we looked for the direction
of effect and where applicable used a random effects
analysis. We also performed a sensitivity analysis by
removing single trials to investigate the extent to
which they contributed to the heterogeneity, particu-
larly looking at baseline characteristics including
severity.
RESULTS
Study characteristics
Of 3257 potentially relevant records identified, 26
were relevant to sore throat, tonsillitis, or pharyngitis
(fig1).Afurther17studieswereexcludedbecausethey
examined postoperative or postintubation sore throat
(13 studies), included inpatients (one), did not have a
placebo group (one), or were duplicate publications
(two). Of the nine that met our inclusion criteria, one
was excluded for not describing the method of
randomisation.
21
The eight studies included 743 patients (369 chil-
dren,374adults):348(47%)hadexudativesorethroat,
and 330 (44%) were positive for group A β-haemolytic
streptococcus.Patientswererecruitedfromemergency
department and general practice settings in four coun-
tries: United States (five studies), Canada (one), Israel
(one), and Turkey (one) (table 1). Corticosteroids used
included betamethasone 2 ml (estimated dose 8 mg,
one study), dexamethasone (up to 10 mg, six studies;
or prednisone 60 mg, one study): doses were reason-
ably comparable for their potency. Corticosteroids
were administered either intramuscularly (three stu-
dies), orally (four), or both (one). Six trials used one
dose of corticosteroids, and two trials prescribed
more than one dose of corticosteroids to a subgroup
ofparticipants.
w1 w2Intheeightincludedstudies,meth-
odological quality was high with a low risk of bias (for
example, all trials reported adequate allocation con-
cealmentandclearmethodsofrandomisation).Table2
reportsthespecificelementsofmethodologicalquality
in the selected studies.
Potentially relevant records for corticosteroids and URTI identified and screened by two reviewers (n=3257)
Potentially relevant records screened by two reviewers (n=440)
Records excluded as not relevant (n=2817)
Articles examining tonsillitis, pharyngitis, and sore throat (n=26)
Articles all meeting inclusion criteria (n=9)
Articles included in review (n=8)
URTI = upper respiratory tract infection
Article excluded on basis of quality (n=1)
Records on other URTI (n=414)
Records excluded because of (n=17):
  Examined post-operative or post intubation
    sore throat  (n=13) 
  Further publications of single studies (n=2)
  No  placebo (n=1)
 Inpatient setting (n=1)
Fig 1 | Flowchart of search results
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Study
Age range
(mean)*
No of patients analysed Severity of sore
throat Intervention Control Antibiotics used Analgesia Outcomes Intervention Control
O’Brien et al
1993 (US)
w8
12–65 (26.4) 26† 25† Severe (GABHS not
tested, 100%
exudative)
Dexamethasone
10 mg (IM)
Saline 1 ml
(IM)
Penicillin G or
erythromycin
Unregulated, no
differences
recorded, type not
reported
Reduction in pain
VAS, time to onset of
pain relief, time to
complete pain
resolution
Marvez-Valls
et al 1998
(US)
w4
14-65 (29.1) 46 46 Severity not stated
(53% GABHS‡,
100% exudative)
Betamethasone
8 mg/2 ml§ (IM)
Saline, 2 ml
(IM)
Penicillin G or
erythromycin
(similar proportion
in each group)
Unregulated,
unrecorded,
paracetamol or
ibuprofen
recommended
Reduction in pain
VAS, time to onset of
pain relief, time to
complete pain
resolution, days
missed from school
or work, percentage
of recurrence
Wei et al 2002
(US)
w6
≥15 (28) 42¶ 37 Severity not stated
(27% GABHS, 43%
exudative)
Dexamethasone
10 mg (PO) +
placebo (IM)¶
Placebo (PO,
IM)
Penicillin V or
erythromycin
Paracetamolforfirst
24 hours as
required, no
differences
recorded
Reduction in VAS,
complete pain
resolution at 24
hours, return to
normal activity,
ability totakeliquids
and solids,
percentage of
recurrence
Bulloch et al
2003
(Canada)
w3
5-16 (9.74) 92 92 Severity not stated
(46% GABHS, 37%
exudative)
Dexamethasone,
0.6 mg/kg (PO,
maximum 10 mg)
Placebo (PO) Penicillin V if DAT
positive
Unregulated,
unrecorded
Reduction in pain
VAS, time to onset of
pain relief, time to
complete pain
resolution,
percentage of
recurrence
Olympia et al
2005 (US)
w5
5–18 (11.9) 57 68 Severe (56%
GABHS, exudative
not stated)
Dexamethasone,
0.6 mg/kg (PO,
maximum 10 mg)
Placebo (PO) Penicillin G,
erythromycin or
azithromycin if DAT
positive or culture
positive
Unregulated, no
differences
recorded,
paracetamol or
NSAIDs
recommended
Reduction in pain,
McGrath score, time
toonsetofpainrelief,
time to complete
pain resolution,
fever, associated
symptoms, need for
further medical care
Kiderman et al
2005
(Israel)
w1
18-65 (33.9) 40 39 Severe (57%
GABHS, 87%
exudative)
Prednisone, 60 mg
for1or2days(PO)**
Placebo (PO) Penicillin V,
amoxicillin,
erythromycin, none
atGP’sdiscretion,or
stopped if culture
negative
Unregulated,
unrecorded
Reduction in VAS
score, proportion of
individuals being
pain-free at various
time points,
percentage of
recurrence,complete
pain resolution at 24
and 48 hours, days
missed from school
or work
Niland et al
2006 (US)
w2
4-21(median
7.7)
30†† 30 Severity not stated
(100%GABHS,57%
exudative)
Dexamethasone,
0.6 mg/kg for 1 day
(PO, maximum
10 mg) + 2 days
placebo
Placebo (PO) 50% received IM
and 50% received
PO antibiotic, type
not stated
Unregulated, no
differences
recorded
Return of general
health, return of
normal activity level,
days missed from
school or work, time
to complete pain
resolution, complete
pain resolution at 24
and 48 hours,
percentage of
recurrence
Tasar et al
2008
(Turkey)
w7
18-65 (31.3) 31 42 Severity not stated
(GABHS not stated,
exudative not
stated)
Dexamethasone,
8m g( I M )
Saline (IM) Azithromycin,
500 mg daily for
3d a y s
Paracetamol for
3d a y sa sr e q u i r e d ,
unrecorded
Timeto onset ofpain
relief, time to
complete pain
resolution, complete
pain resolution at 24
and 48 hours
GABHS=group A β-haemolytic streptococcus. IM=intramuscular delivery. PO=oral delivery. DAT=direct antigen test. VAS=visual analogue scale.
*Age in years. Value in parentheses is the mean unless stated otherwise.
†13 participants in each arm available for follow-up at 7 days to determine complete resolution.
‡84% of participants had throat cultures taken, percentage is reported as if all participants had cultures.
§Dose is a best guess from US formularies.
¶Third arm of trial examining IM dexamethasone not included in general analysis.
**Data from two doses of corticosteroid versus one dose not presented separately.
††Third arm of trial evaluating three daily doses of dexamethasone not included in meta-analysis.
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tion at 24 hours (four studies) and 48 hours (three stu-
dies),meantimetoonsetofpainrelief(five),meantime
to complete resolution of pain relief (six), reduction in
visual analogue scale pain score (five), number of days
missed from school or work (three), and recurrence
rates (four). All eight trials prescribed antibiotics to
both intervention and placebo groups and allowed
simple analgesia. In four trials, analgesia use was
recorded, which was not significantly different
betweenplacebo and corticosteroid groups.Two trials
restricted analgesia to paracetamol for 24 hours or 72
hours, recording no difference in use
w6 and not report-
ing use
w7 respectively. Four trials reported outcomes
separatelyforpatientspositiveandnegativeforbacter-
ial pathogens.
w3-w6
Complete resolution of pain at 24 or 48 hours
Inapooledanalysisoffourtrials
w1 w2 w6 w7patientstrea-
tedwithcorticosteroidswerethreetimesmorelikelyto
have complete resolution of pain at 24 hours (relative
risk 3.2, 95% confidence interval 2.0 to 5.1, P<0.001,
I
2=44%) (fig 2). The number needed to treat was 3.7
(2.8 to 5.9). Significant effects were recorded in adult
patientsonly(relativerisk4.3,2.3to8.1,P<0.001)
w1 w6 w7
and in those receiving oral corticosteroids only (2.6,
1.6 to 4.3, P<0.001).
w1 w2 w6 Data were insufficient to
undertake further subgroup analysis.
In three trials
w1 w2 w7 corticosteroids also increased
the likelihood of complete resolution of pain at 48
hours (relative risk 1.7, 95%CI 1.3 to 2.1, P<0.001),
number needed to treat was 3.3 (2.4 to 5.6) (fig 2).
Results were similar in trials with adult patients only
(1.8, 1.3 to 2.3, P<0.001)
w1 w7 and in those receiving
oral corticosteroids only (1.6, 1.2 to 2.1, P=0.004).
w1 w2
Mean time to onset of pain relief
Sixtrialsreportedthemeantimetoonsetofpainrelief,
which occurred at an average of 6.3 hours earlier with
corticosteroids than without (95% CI 9.3 to 3.4,
P<0.001) (fig 3).
w3-w8 The wide variation in individual
response times caused high heterogeneity (I
2=73%). A
sensitivity analysis, which excluded each trial in turn,
demonstrated a range of weighted mean difference of
5.1to7.2hours,butnolossofsignificance.Themajor-
ity of the heterogeneity arose from the trialby Tasar et
al, which showed the largest benefit of corticosteroids
with small standard deviations.
w7 Removal of this trial
from the meta-analysis gave a mean time to onset of
pain relief 5.1 hours earlier in patients given corticos-
teroids.
Inpatientswithanexudativesorethroat,corticoster-
oids also reduced the mean time to onset of pain relief
(weighted mean difference 6.2 hours, 8.4 to 4.0). Simi-
larly, we recorded a reduction in mean time to pain
reliefinsorethroatthatwasbacterialpathogenpositive
(5.3, 8.0 to −2.6) and in trials selecting for severe sore
throat (7.2, 10.1 to 4.3). All three categories of sore
throat (exudative, bacterial pathogen positive, and
severe)weresignificant(P<0.001)withnoheterogene-
ity (I
2=0) (fig 4).
Thedirectionofeffectformeantimetoonsetofpain
reliefwassimilarintrialswithadultsonly,intrialswith
intramuscular and oral routes of steroid administra-
tion, and in trials in which severe sore throat was not
Table 2 |Methodological quality of included studies (see web appendix for references)
Study
Allocation
concealment Randomisation
Comparability of groups
at baseline Blinding Participation (%)
Provision of care
apart from
intervention
O’Brien et al (1993)
w8 Adequate Random number table Comparable Double 88 Equal
Marvez-Valls et al (1998)
w4 Adequate Randomised list Comparable Double 100 Equal
Wei et al (2002)
w6 Adequate Randomisationschemeheldatcentral
pharmacy
Comparable Double 92.5 Equal
Bulloch et al (2003)
w3 Adequate Block randomisation, held at central
pharmacy
Comparable Double 97 Equal
Olympia et al (2005)
w5 Adequate Block randomisation Comparable Double 83 Equal
Kiderman et al (2005)
w1 Adequate Random number table Comparable Double 100 Equal
Niland et al (2006)
w2 Adequate Block randomisation Comparable, apart from
gender, which had no
significant effect on results
Double 93 Equal
Tasar et al (2008)
w7 Adequate Random number table Comparable Double 100 Equal
  Kidermanw1
  Nilandw2
  Tasarw7
  Weiw6
Total
Heterogeneity: I2=44%
4.14 (1.53 to 11.22)
1.67 (0.80 to 3.45)
8.81 (2.14 to 36.23)
2.63 (0.93 to 7.45)
3.16 (1.97 to 5.08)
23.0
43.1
9.7
24.2
100.0
Study
24 hours
Relative risk
(fixed) (95% CI)
Relative risk
(fixed) (95% CI)
Weight
(%)
17
12
13
12
54
Events
40
27
31
41
139
Total
Steroid
4
8
2
4
18
Events
39
30
42
36
147
Total
Placebo
  Kidermanw1
  Nilandw2
  Tasarw7
Total
Heterogeneity: I2=0%
1.73 (1.03 to 2.89)
1.44 (1.00 to 2.06)
1.79 (1.32 to 2.42)
1.65 (1.32 to 2.06)
27.5
33.6
39.0
100.0
0.05 0.2 1 5 20
48 hours
Favours
placebo
Favours
steroid
23
22
29
74
40
27
31
98
13
17
22
52
39
30
42
111
Fig 2 | Effect of corticosteroids on number of patients experiencing complete pain relief at 24
and 48 hours. See web appendix for references
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than 50% exudative sore throat, and non-bacterial
pathogen positive only did not reach significance .We
did not find significant changes in mean time to onset
ofpainreliefin trialswithchildrenonly,trialswithless
than50%exudativesorethroat,andinthesubgroupof
patients with sore throat not positive for bacterial
pathogens. Meta-regression analysis revealed no sig-
nificant differences across all subgroups (fig 4).
Figure5showsthechangeinvisualanaloguescaleat
baselineto72hours.ThedatafromBullochetal’strial
display the lowest baseline visual analogue scale score
(that is, less severe) and the least response at 24 and 48
hours.
w3 This finding is reflected in the non-significant
effect (and the smallest effect) observed in the mean
time to onset of pain relief for this trial.
Time to complete resolution of symptoms
Five trials assessed the mean time to complete resolu-
tion of pain.
w3-w5 w7 w8 High heterogeneity prevented
pooling: three studies showed a benefit of corticoster-
oids,
w5 w7 w8 and two showed non-significant effects in
opposing directions. Time to complete resolution
ranged from 15 to 45 hours in the corticosteroid
group and 35 to 54 hours in the placebo group.
Adverse events, relapse rates, and days missed from
school or work
Only one trial
w5 of 125 participants reported adverse
events: five patients (three steroid, two placebo) were
hospitalised for fluid rehydration, and three patients
developed peritonsillar abscess (one steroid, two pla-
cebo).Threestudiesreportednosignificantdifferences
in days missed from school or work.
w1 w2 w4 Four trials
reported no difference in the incidence of recurrent
symptoms
w1-w4 (measured between 5 days and
1 month after treatment), whereas one trial found sig-
nificantlyincreasedrecurrenceintheplacebogroup.
w6
DISCUSSION
Corticosteroidssignificantlyincreasetheproportionof
patientswithsorethroatwhowillexperiencecomplete
resolution of pain at both 24 and 48 hours. Fewer than
four patients need to be treated to prevent one patient
continuing to experience a painful sore throat at 24
hours. Although corticosteroids decreased the mean
time to onset of pain relief by 6 hours, pooled analysis
showed significant heterogeneity. All effects were in
addition to antibiotic use.
We found that the effects of corticosteroids on mean
timetoonsetofpainreliefwerehomogenousinsevere,
exudative, or bacterial pathogen positive sore throat
alone. Our data do not support an effect in mild sore
throat because only one study included patients with
milder symptoms at baseline, and showed no signifi-
cant effect. A meta-regression analysis showed no evi-
dence of interactions across different subgroups (such
asrouteofcorticosteroid,age,severity)ontheoutcome
of mean time to onset of pain relief.
The effects of corticosteroids on resolution of pain
were most apparent in the initial 24 hours, which
impliesthatasingledoseofcorticosteroidsmaybesuf-
ficient.Thiseffectissimilartothatseenincroupwhere
a single dose is generally adequate.
17 Furthermore, the
one trial comparing three daily doses of dexametha-
sone with a single dose found no difference in effect.
w2
Limitations
Our analysis had some limitations. Firstly, and most
importantly, all of the included trials provided anti-
biotics to patients in both corticosteroid and placebo
groups (either to all participants, or to all participants
with group A β-haemolytic streptococcus culture or a
positiverapidantigentest).Therefore,wedonotknow
the effects of corticosteroids on sore throat symptoms
independent of antibiotics.
Secondly,variousoutcomemeasureswerereported,
in some cases with inadequate reporting, no standard
deviations, or use of graphical representation only.
Thirdly, significant heterogeneity occurred in some
of our analyses; this was attributable mainly to one
trial,
w7 which demonstrated increased benefit of corti-
costeroids with small standard deviations. However,
ourresultsremainedrobusttothe removalofthistrial.
  Bullochw3
  Marvez-Valls
w4
  O’Brien
w8
  Olympia
w5
  Tasar
w7
  Wei
w6
Total
Heterogeneity: I2=72%
-0.50 (-5.59 to 4.59)
-5.00 (-8.31 to -1.69)
-6.10 (-9.81 to -2.39)
-9.00 (-13.77 to -4.23)
-11.80 (-15.13 to -8.47)
-4.67 (-7.97 to -1.37)
-6.32 (-9.29 to -3.35)
13.9
18.1
17.1
14.6
18.1
18.2
100.0
Study
Mean difference
(random) (95% CI)
Mean difference
(random) (95% CI)
Weight
(%)
9.6
6.3
6.3
9.2
8.1
7.4
Mean
19.4
8.1
5.3
7.5
4.9
5.3
SD Mean SD
Steroid
10.1
11.3
12.4
18.2
19.9
12.07
15.6
8.1
8.5
18.3
9.4
8.7
92
46
31
57
31
42
299
Total Total
92
46
27
68
42
35
310
Placebo
-20 -10 0 10 20
Favours
steroid
Favours
placebo
Fig 3 | Effect of corticosteroids on mean time to onset of pain relief in hours. See web appendix
for references
Child
Adult
PO
IM
Bacterial-pathogen-positive
Bacterial-pathogen-negative
<50% exudate
100% exudate
Severity not stated
Severe
-4.8 (-13.0 to 3.5)
-6.9 (-10.0 to -3.6)
-4.8 (-9.0 to -0.5)
-6.9 (-10.0 to -3.6)
-3.9 (-9.2 to 1.4)
-5.3 (-8.0 to -2.6)
-3.0 (-7.0 to -0.9)
-5.5 (-8.0 to -3.0)
-5.7 (-10.0 to -1.4)
-7.2 (-10.0 to -4.3)
Subgroups
Weighted
mean difference
(random) (95% CI)
Weighted
mean difference
(random) (95% CI)
82
74
65
73
67
0
45
0
82
0
I
2
(%)
2
4
3
4
4
4
2
2
4
2
Trials
(n)
309
300
386
297
247
208
261
150
426
183
Patients
(n)
0.57
0.44
0.32
0.28
0.64
Interaction
-10 -15 -5 0 5 10
Fig 4 | Effect of corticosteroids on mean time to onset of pain relief analysed by subgroup using
meta-regression. PO=oral delivery. IM=intramuscular delivery
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onset of pain relief was limited by recall bias, because
theestimationofthetimewhenpainreliefbeginsrelies
onpatients’ subjectiverecall and recording.Themean
time could also be skewed by a few participants who
had sore throat pain for especially long or short peri-
ods. A median time may have been more appropriate,
althoughtherewereinsufficientdataforustocalculate
this.
Finally, the limited number of trials meant that we
were unable to assess publication bias using funnel
plots, although we attempted to address this issue by
using citation searching. Included studies were also
underpowered to detect rare adverse effects of corti-
costeroid therapy, as well as relapse rates and days
missed from work or school.
Implications for practice
Ourfindingssuggestthatinpatientswithsevereorexu-
dative sore throat, pain can be reduced and resolution
hastened by use of corticosteroids in conjunction with
antibiotic therapy. Current UK practice is to assessthe
likelihoodofgroupAstreptococcusinfectionusingthe
Centor criteria
22 (tender lymphadenopathy, exudate,
fever, absence of cough). Our research suggests that
patientswith severeor highCentor scoringsore throat
would benefit from a single dose of corticosteroids.
The use of corticosteroids will triple the likelihood of
resolution at 24 hours and hasten this resolution by
more than 6 hours, even in patients who have also
been given antibiotics and analgesics.
Our findingthatthe durationof painisreducedby 6
hoursseemsmodest.However,thedecisiontouseany
treatment involves balancing the benefit and potential
harms of the therapy. Although our included studies
were not sufficiently powered to detect adverse effects
of short courses of oral corticosteroids, the treatment
has been associated with little morbidity in the man-
agement of croup and asthma. Moreover, treatment
is commonplace for other short lasting illnesses that
cause distress for patients, such as antibiotics for cysti-
tis. In this context, onset of pain relief 6 hours earlier
may be an acceptable benefit to many patients, and
may prevent antibiotic use (particularly in the context
of delayed prescriptions).
Wecouldnotfullyassessthebesttype,route,ordos-
ingregimenofcorticosteroidsbecauseofsmallsample
sizes. Two studies which directly compared intra-
muscular and oral routes found no differences, and
our subgroup comparison also showed no
differences.
23 w6 Therefore, the current evidence
showsthatoralcorticosteroidsareasbeneficialasintra-
muscular preparations and are more acceptable to
patients.
In the included studies antibiotic use could reflect
clinical practice in North America, where most of the
trials were performed. Prescribing and consultation
patterns may be different in the UK or Europe, where
no trials were undertaken. Therefore, additional trial
data are warranted in European populations before
the results can be deemed generalisable. We are also
unsure of the benefits of corticosteroids in children
because of the limitations on the reporting in these
trials.
Recommendations for research
Future trials should be in antibiotic naïve patients, and
include the number of patients who have resolution of
symptoms at 24, 48, and 72 hours and standardised
pain scores. They should be large enough to ade-
quately assess adverse events and days missed from
school or work. Use of the Centor criteria at baseline
will facilitate classification of severity. Any effects of
corticosteroids on potentially reducing antibiotic use
will need to be balanced by the risk of medicalising
what is usually a self limiting and short lasting infec-
tion. Further research should focus on the effects of
corticosteroids on antibiotic use as well as longer
term measures such as reattendance with recurrent
sore throats. Additionally, further trials in children
arewarrantedthatadequatelyreporttheoutcomemea-
sures outlined above.
Summary
Corticosteroids, in addition to antibiotics, provide
symptomaticreliefofpaininsorethroat.Inthecurrent
analysis, most participants had severe or exudative
sore throat. Subgroup analyses showed no significant
differences between trials, including severe sore
throats and those in which severity was not stated.
We found no evidence of significant benefit in chil-
dren. Further research should target corticosteroid
use in antibiotic-naïve patients.
Steroid
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Fig 5 | Mean pain score on visual analogue scale at baseline
and after corticosteroids or placebo. See web appendix for
references
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Corticosteroids are beneficial for symptoms of upper respiratory tract infections
Sore throat is a common condition in primary care
Recent guidelines recommend that antibiotics should not be prescribed for sore throat
WHAT THIS STUDY ADDS
At 24 hours, patients with severe sore throat who are given corticosteroids in addition to
antibiotics are three times more likely to report complete resolution of symptoms than those
who do not receive corticosteroids
Corticosteroids also reduce the time to mean onset of pain relief in this patient group by
about 6 hours
The effect of corticosteroids independent of antibiotics is unknown and should be the focus
of future research
RESEARCH
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